Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients.
Chai SJ, Fong SCY, Gan CP, Pua KC, Lim PVH, Lau SH, Zain RB, Abraham T, Ismail SM, Abdul Rahman ZA, Ponniah S, Patel V, Cheong SC, Lim KP. Chai SJ, et al. Among authors: ponniah s. Hum Vaccin Immunother. 2019;15(1):167-178. doi: 10.1080/21645515.2018.1520584. Epub 2018 Oct 12. Hum Vaccin Immunother. 2019. PMID: 30193086 Free PMC article.
Monitoring circulating tumor cells in cancer vaccine trials.
Gates JD, Benavides LC, Stojadinovic A, Mittendorf EA, Holmes JP, Carmichael MG, McCall S, Milford AL, Merrill GA, Ponniah S, Peoples GE. Gates JD, et al. Among authors: ponniah s. Hum Vaccin. 2008 Sep-Oct;4(5):389-92. doi: 10.4161/hv.4.5.6115. Epub 2008 Sep 16. Hum Vaccin. 2008. PMID: 18437056
Folate receptor α: a storied past and promising future in immunotherapy.
Clifton GT, Sears AK, Clive KS, Holmes JP, Mittendorf EA, Ioannides CG, Ponniah S, Peoples GE. Clifton GT, et al. Among authors: ponniah s. Hum Vaccin. 2011 Feb;7(2):183-90. doi: 10.4161/hv.7.2.13784. Epub 2011 Feb 1. Hum Vaccin. 2011. PMID: 21321484 Review.
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S, Peoples GE. Mittendorf EA, et al. Among authors: ponniah s. Cancer. 2012 May 15;118(10):2594-602. doi: 10.1002/cncr.26574. Epub 2011 Oct 11. Cancer. 2012. PMID: 21989902 Free PMC article. Clinical Trial.
Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.
Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, Peoples GE. Woll MM, et al. Among authors: ponniah s. J Clin Immunol. 2004 Jul;24(4):449-61. doi: 10.1023/B:JOCI.0000029117.10791.98. J Clin Immunol. 2004. PMID: 15163902
Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE. Hueman MT, et al. Among authors: ponniah s. Clin Cancer Res. 2005 Oct 15;11(20):7470-9. doi: 10.1158/1078-0432.CCR-05-0235. Clin Cancer Res. 2005. PMID: 16243821 Clinical Trial.
97 results